KPL

Kwality Pharmaceuticals Targets ₹700 Crore Revenue in FY27 Following Guidance Revision

Kwality Pharmaceuticals revises FY27 revenue target to ₹700Cr+ and eyes ₹1,500Cr by FY30. Highlights include biosimilar expansion and 26-27% EBITDA margins.

Kwality Pharmaceuticals · 12 Aug 2026, 3:35 PM IST